Originally published by our sister publication Clinical Oncology News
The FDA has announced its final decision to withdraw approval of melphalan flufenamide (Pepaxto, Oncopeptides), which was being used under an accelerated approval for use in combination with dexamethasone to treat certain patients with multiple myeloma. 
The agency determined the following grounds for withdrawal were met:
—The confirmatory study conducted as a condition of accelerated